Article Details

HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200604, a Best-in ...

Retrieved on: 2024-11-04 17:34:02

Tags for this article:

Click the tags to see associated articles and topics

HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200604, a Best-in .... View article details on hiswai:

Summary

The article highlights HiFiBiO Therapeutics' FDA clearance for its monoclonal antibody, HFB200604, a BTLA agonist targeting autoimmune diseases. This relates to biotech by demonstrating advances in immunotherapy and antibody development.

Article found on: pipelinereview.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up